



Establishment of a Tailor-made Therapy Based on the Disease-stage of 
Sjögren's Syndrome
Masayuki AZUMA
Abstract：Sjögren's syndrome (SS) is one of the most common rheumatic diseases. Histopathologic 
features of SS salivary glands include: (a) the eventual total replacement of the acinar structure by 
marked lymphocytic infiltrate and (b) the occurrence of various changes in the ductal structure within 
infiltrated areas, such as metaplasia, hyperplasia, thinning of ductal layer, or oncocytic change, and in 
some cases the formation of epimyoepithelial islands arising from ductal proliferation. Accordingly, 
surviving and/or proliferating ductal cells in SS salivary glands may be regarded as one of the possible 
sources for the improvement of salivary secretion. Thus far, I found that inhibition of TNF-α-induced 
MMP-9 production in acinar cells lead to restored integrity of the acinar structure in SS salivary 
glands. Therefore, in this review I would like to postulate a tailor-made therapy based on the disease-
stage of SS. First, therapy for the inhibition of lymphocytic infiltrate into salivary glands by regulating 
balance of sex hormones in acinar cells (early stage of SS); second, therapy for the maintenance of 
stable acinar structure by inhibiting cytokine-induced basement membrane-degrading enzymes, such 
as MMP-9 (intermediate stage of SS); and third, therapy for the bestowal of ability to secrete saliva on 
ductal cells (late stage of SS). Hopefully, these disease stage-specific therapies would contribute to the 
improvement of QOL of SS patients.
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sulphate（DHEA-S） は steroid sulfatase（STS） に よ り
DHEAに変化し，また steroid sulfotransferase（SULT2M）
により DHEA-S に変わる。細胞内の DHEA は 17-β-







anti-human STS, goat anti-human SULT2M, goat anti-human 
3-β-HSD, goat anti-human 17-β-HSD, goat anti-human 5-α



















STS: steroid sulphatase, 
SULT: steroid sulfotransferase, 
3-β-HSD: 3-β-hydroxysteroid dehydrogenase, 
17-β-HSD: 17-β-hydroxysteroid dehydrogenase, 
DHEA-S: dehydroepiandrosterone sulphate, 
TEST: testosterone, DHT: dihydrotestosterone.




























































織における p65，リン酸化 IκB-α，MMP-9 および type IV 
collagenの発現については，セファランチン未投与マウ
スにおいては p65とリン酸化 IκB-α，MMP-9 の強い発現
が認められたが，セファランチン投与マウスにおいて
は p65とリン酸化 IκB-α，MMP-9 の著しい発現低下が観
察された。そして基底膜構成成分である type IV collagen
の断裂がセファランチン未投与マウスにおいては認めら
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